Entering text into the input field will update the search result below

Xencor's (XNCR) CEO Bassil Dahiyat on Q1 2018 Results - Earnings Call Transcript

May 07, 2018 9:34 PM ETXencor, Inc. (XNCR)
SA Transcripts profile picture
SA Transcripts

Xencor, Inc. (NASDAQ:XNCR) Q1 2018 Earnings Conference Call May 7, 2018 4:30 PM ET


Josh Rappaport - Stern, IR

Bassil Dahiyat - President & CEO

John Desjarlais - Chief Scientific Officer

John Kuch - VP, Finance


Edward Tenthoff - Piper Jaffray

Arlinda Lee - Canaccord Genuity

David Nierengarten - Wedbush Securities


Good afternoon and welcome to the Xencor First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. Following the formal remarks, we will open up the call up for questions. Please be advised that this call is being recorded at the Company's request.

At this time, I would like to turn the call over to Josh Rappaport of Stern Investor Relations. Please proceed.

Josh Rappaport

Thank you, operator. Good afternoon, this is Josh Rappaport with Stern Investor Relations. Welcome to Xencor's first quarter 2018 financial results conference call.

Earlier this afternoon, we issued a press release which outlines the topics we plan to discuss today. The release is available at www.xencor.com. Today, on our call, Bassil Dahiyat, Ph.D., President and Chief Executive Officer, will discuss the Company's business highlights and provide an update on Xencor's clinical programs; John Desjarlais, Chief Scientific Officer, will discuss preclinical progress; and John Kuch, Vice President of Finance, will review the financial results from the first quarter of 2018. Then, we will open up the call for your questions.

Before we begin, I would like to remind you that during the course of this conference call, Xencor management may make forward-looking statements, including statements regarding the Company's future financial and operating results, future market conditions, the plans and objectives of management for future operations, the Company's partnering efforts, the Company's capital requirements, the Company's future product offerings, and the Company's research and development programs. These forward-looking statements are not historical facts, but rather are based on

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.